Extracellular and nuclear PD-L1 in modulating cancer immunotherapy.
Extracellular and nuclear PD-L1 in modulating cancer immunotherapy.
复制标题
DOI：
10.1016/j.trecan.2021.03.003
复制
发表时间：
2021-04
期刊：
影响因子：
18.4
通讯作者：
Wenjun Xiong;Yang Gao;Wenyi Wei;Jinfang Zhang
中科院分区：
文献类型：
--
作者：
Wenjun Xiong;Yang Gao;Wenyi Wei;Jinfang Zhang
尽管靶向程序性死亡1/程序性死亡配体1（PD-1/PD-L1）在某些癌症患者中实现了持久的缓解和疾病缓解，但相对较低的缓解率和新出现的耐药性限制了其临床应用。因此，更深入地了解PD-1/PD-L1轴的调节机制对于开发克服PD-1/PD-L1阻断障碍的联合治疗策略至关重要。越来越多的证据表明，PD-L1可以分泌到细胞外空间或易位到细胞核中，这在调节癌症免疫逃避、肿瘤发生和免疫治疗中也起着关键作用。本文综述了细胞外和细胞核PD-L1在转化医学中的作用，并讨论了其未来的研究方向和潜在的机会。
Although targeting programmed death 1/programmed death ligand 1 (PD-1/PD-L1) has achieved durable responses and disease remission in patients with certain cancers, relatively low response rates and emerging resistance limit its clinical application. Hence, a more thorough understanding of regulatory mechanisms of the PD-1/PD-L1 axis is vital for developing combined therapeutic strategies to overcome hurdles of PD-1/PD-L1 blockade. Increasing evidence has demonstrated that PD-L1 can be secreted into the extracellular space or translocated into the nucleus, which also plays a critical role in regulating cancer immune evasion, tumorigenesis, and immunotherapy. In this review, we summarize these emerging roles of extracellular and nuclear PD-L1 and discuss future research directions and potential opportunities in translational medicine.